Drug
Biological Ntla 3001
Biological Ntla 3001: highest development phase Phase 1/2, developed by Intellia Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Intellia Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Biological NTLA-3001 NCT06622668 | Phase 1/2 | Lung Disease |
Latest
No recent events.
Follow Biological Ntla 3001 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.